美国FDA《药物开发中新方法应用的一般考虑》指南草案解读OA
Interpretation of FDA Draft Guidance:General Considerations for the Use of New Approach Methodologies in Drug Development
类器官、器官芯片、计算机建模等新方法正引领药物研发范式的革新,科学评估其技术的适用性、可靠性与可重复性,已成为推动新方法合规应用、获得监管认可、赋能生物医药创新的关键.2026年3月,美国食品药品监督管理局(FDA)药品审评与研究中心发布《药物开发中新方法应用的一般考虑》指南草案,系统提出新方法在药物研发中的验证框架与应用准则,旨在推动非动物替代方法替代传统动物试验,提升药物研发效率.本文通过对指南草案制定背景、核心概念的深度解读,重点剖析 FDA 构建的新方法四维验证框架的核心要求与实操要点,分析其对我国药物研发行业的核心价值与实践启示,并结合我国医药研发及监管现状,提出我国新方法监管思路,为新方法在我国药物研发中的合规应用与监管采纳提供参考.
New approach methodologies(NAMs),including organoids,organ-on-a-chip technologies,and computational modeling,are driving a paradigm shift in drug research and development.Scientifically evaluating their applicability,reliability,reproducibility,and fitness for purpose has become critical to facilitating their appropriate use,gaining regulatory acceptance,and advancing pharmaceutical innovation.In March 2026,the U.S.Food and Drug Administration(FDA),through its Center for Drug Evaluation and Research(CDER),issued the draft guidance General Considerations for the Use of New Approach Methodologies in Drug Development.This draft guidance establishes a validation framework and provides general recommendations for the use of NAMs in drug development,with the aim of facilitating the reduction and replacement of animal testing and improving the efficiency and human relevance of drug development.This paper provides an in-depth interpretation of the background and key concepts of the draft guidance,with particular emphasis on the core requirements and practical considerations of the FDA's four-dimensional validation framework for NAMs.It further analyzes the implications of the draft guidance for China's pharmaceutical research and development sector and,in light of the current landscape of pharmaceutical development and regulatory science in China,proposes recommendations for the regulatory adoption of NAMs.The study aims to provide a reference for the compliant application and regulatory acceptance of NAMs in drug development in China.
赵曼曼;周晓冰
中国药品检定研究院药品监管科学全国重点实验室中国药品检定研究院药品监管科学全国重点实验室
医药卫生
新方法指南草案验证药物研发替代
new approach methodologiesdraft guidancevalidationdrug developmentalternative methods
《中国食品药品监管》 2026 (8)
58-65,8
药品监管科学全国重点实验室课题(2026SKLDRS03080)
评论